


duplicate
of P.P.
#10



PATENT
Attorney Docket No. 219603
Client Reference No. KAUS430501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kasid et al.

Application No.: 09/930,283

Filed: August 16, 2001

For: **LIPOSOMES CONTAINING
OLIGONUCLEOTIDES**

Art Unit: 1635

Examiner: T. Gibbs

RECEIVED
SEP 17 2003
TECH CENTER 1600/2900

RESPONSE TO OFFICE ACTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated August 26, 2003, please enter the following amendments and consider the following remarks.

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8			
I hereby certify that this Response to Office Action and all accompanying documents are, on the date indicated below, <input checked="" type="checkbox"/> being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or <input type="checkbox"/> being facsimile transmitted to the U.S. Patent and Trademark Office, Attention: Examiner T. Gibbs, Art Unit 1635, Facsimile Number			
Name (Print/Type)	M. Daniel Hefner		
Signature		Date	September 11, 2003

Amendments to the Abstract:

Please replace the paragraph appearing on page 31 of the application under the section heading "Abstract" with the following (note the underlining of "c-raf-1" in the second line is formatting from the original; it does not signify an amendment):

It is possible to radiosensitize tumor cells by administration of compositions containing the Human antisense c-raf-1 oligodeoxyribonucleotide (ODN/oligo) sequence: 5'-GTGCTCCATTGATGC-3' (~~seq. #1~~) (SEQ ID NO: 1) wherein only the end bases are phosphorylated in a preferred embodiment. Antisense sequences of up to 40 bases ~~which~~ containing this sequence may be used in accord with the teachings of this disclosure. Compositions comprising a cationic liposome of dimethyldioctadecyl ammonium bromide, phosphatidylcholine and cholesterol may be used as a carrier system. The liposomes provide a new carrier system that is particularly useful for administration of sequences for therapy.